A Study to Determine the Effect of Endogenous Glucagon-Like Peptide-1 on Active Intestinal Glucose Transport and Intestinal Permeability

Overview

About this study

The purpose of this study is to determine the effect of endogenous glucagon-like peptide-1 on active intestinal glucose transport and on intestinal permeability.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria

Have had a Roux en Y gastric bypass at least 1 year prior to study
No current diagnosis of diabetes
Also a control group will be recruited of non-diabetic subjects who are age, gender and weight-matched to the RYGB subjects
All participants will have good health, be at a stable weight, and not engage in regular vigorous exercise

Exclusion Criteria

< 20 years of age or > 65 years of age to minimize the potential confounding effects of age on glucose absorption and metabolism
Any known active systemic illness or chronic disease
Prior abdominal surgery other than cholecystectomy, appendectomy or Roux en Y gastric bypass

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location	Status
Rochester, Minn. Mayo Clinic principal investigator Adrian Vella, M.D.	Closed for enrollment

Mayo Clinic Location

Status

Rochester, Minn.

Mayo Clinic principal investigator

Adrian Vella, M.D.

Closed for enrollment

More information

Publications

Publications are currently not available

Clinical Trials